Zydus Cadila Gets USFDA Nod For Ezetimibe Tablets


Zydus Cadila has received a final approval from the USFDA to market Ezetimibe Tablets USP, 10 mg, informed Cadila Healthcare on Tuesday.

Ezetimibe is a drug used to reduce high cholesterol levels. It will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Meanwhile, Cadila Healthcare was up 0.8% at Rs 552.90 per share at 1005 hours IST on BSE. The stock has hit a high of Rs 557.05 and a low of Rs 545.55 per share.

Cadila Healthcare attracted the trading volume of 8,13,234 shares at 1005 hours IST. The stock has delivered more than 70% returns over a period of 1 year. It has outperformed BSE Sensex and BSE Healthcare over the same period.

Cadila Healthcare Ltd is a research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔

Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: